# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Barclays analyst Travis Steed maintains Becton Dickinson (NYSE:BDX) with a Overweight and raises the price target from $305 ...
BD reports Q2 sales of $5.04 billion, up 4.6% Y/Y. BD Medical, Life Sciences, and Interventional segments show growth. Guidance...
Becton, Dickinson (NYSE:BDX) reported quarterly earnings of $3.17 per share which beat the analyst consensus estimate of $2.97 ...
The new BD FACSDiscover S8 Cell Sorters feature BD CellView Image Technology, profiled on the cover of the journal Science in 2...
AngioDynamics resolves decade-long patent litigation with Becton, Dickinson in landmark settlement, streamlining legal expenses...
Under the terms of the settlement, BD will grant a license to AngioDynamics under certain of BD's port patents and AngioDyn...